Herbalife Ltd. — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016; the filing also reports fourth-quarter results. Herbalife is a global nutrition company selling primarily through independent Members in 94 countries. Formula 1 Healthy Meal accounted for approximately 30% of net sales.
Financial performance and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Net sales | $4,488.4 million | $4,469.0 million |
| Gross profit / gross margin | $3,633.8 million / 81.0% | $3,613.0 million / 80.9% |
| Operating income / margin | $458.1 million / 10.2% | $583.6 million / 13.1% |
| Net income | $260.0 million | $339.1 million |
| Diluted EPS | $3.02 | $3.97 |
| Cash from operating activities | $367.3 million | $628.7 million |
| Capital expenditures | $144.3 million | $79.1 million |
| Cash and cash equivalents at year-end | $844.0 million | $889.8 million |
| Total debt at year-end | $1,447.9 million | $1,622.0 million |
| Working capital at year-end | $671.0 million | $541.9 million |
The filing reports FY2016 net sales growth of 6.3% in local currency, with worldwide Volume Points up 4.6%. Foreign-exchange movements reduced reported sales by approximately 5.8%. Gross margin improved 10 basis points, while royalty overrides were 28.4% of sales and SG&A was 43.8% of sales. No dividends were paid or declared in 2016; the company made no open-market share repurchases.
Fourth quarter: Net sales were $1,045.0 million versus $1,098.4 million in Q4 2015; net income was $99.4 million versus $84.5 million.
Material changes and operating trends
- Annual sales were nearly flat in reported dollars, but improved in local currency. Growth was uneven: EMEA sales rose 8.0%, North America 8.7%, and China 2.7%; South and Central America fell 14.2%, while Asia Pacific excluding China declined 2.7%.
- Net income fell 23.3%. The main identified pressure was a $203.0 million pre-tax charge for regulatory settlements, partly offset by higher China government grants, a $29.7 million arbitration award, lower Venezuela-related foreign-exchange losses, and lower income taxes.
- Operating cash flow declined by $261.4 million year over year. Capital expenditures increased, primarily reflecting investment in manufacturing, systems, warehouses, and sales centers.
- China net sales increased, but management cited slower growth and a Q4 Volume Point decline as Members tested less-sustainable business methods.
Outlook, risks, contingencies, and unusual items
- FTC Consent Order: Effective July 25, 2016, it resolved the FTC’s multi-year investigation. Herbalife paid $200 million and agreed to U.S. member classifications, compensation tied to retail sales, restrictions affecting Nutrition Clubs, compliance records and audits by an independent auditor for seven years. Most implementation steps were due by May 2017. Management did not expect a long-term material adverse impact, but acknowledged potential near-term effects, costs, and compliance risk.
- Guidance and investment: The company expected 2017 capital expenditures of approximately $125 million to $155 million. Management warned that U.S. sales could be negatively affected during 2017 as the company and Members adjusted to Consent Order requirements. No numerical revenue or earnings guidance is provided in the supplied filing text.
- Debt and refinancing: Year-end debt included $410 million outstanding under the revolving credit facility and $1.15 billion principal amount of 2.00% convertible notes due in 2019. The prior credit facility matured in March 2017. On February 15, 2017, Herbalife entered a new $1.45 billion secured facility, including a $1.3 billion term loan and $150 million revolver, and repaid the prior $410 million balance. The board approved a new $1.5 billion, three-year share repurchase program on February 21, 2017.
- Legal, tax, and regulatory exposure: The company disclosed ongoing tax disputes and audits in multiple jurisdictions, including Mexico, Brazil, India, and Korea, and said outcomes were uncertain. The SEC and Department of Justice requested information concerning anti-corruption compliance in China; the company was cooperating and could not predict the outcome. Product liability claims and challenges to its network marketing model also remain risks.
- Foreign-exchange and country risks: Approximately 80% of sales were outside the U.S. Venezuela faced inflation, pricing and import restrictions, and currency controls that limited access to U.S. dollars. The company reported $7.2 million of Venezuela-related foreign-exchange losses and charges in 2016. China’s direct-selling rules, licensing, and enforcement remain uncertain.
- Other unusual items: Other operating income of $63.8 million included $34.2 million in China government grants and a $29.7 million arbitration award. The company announced a CEO succession plan: COO Richard Goudis was to become CEO on June 1, 2017, with Michael Johnson becoming Executive Chairman.
Most important facts for investors to verify
- Whether Consent Order implementation, retail-sales documentation, and the independent compliance audits affect U.S. sales, Member retention, compensation, or costs.
- Whether local-currency sales and Volume Point growth persist, particularly in China, South and Central America, South Korea, and Brazil.
- Cash generation and spending needs after the 2016 decline in operating cash flow and increase in capital expenditures; confirm refinancing terms and covenant headroom under the new facility.
- Developments in tax assessments, the China anti-corruption inquiry, and other legal or regulatory matters, including any changes to recorded reserves.
- Exposure to currency controls and devaluations, especially in Venezuela, and the sensitivity of reported results to foreign-exchange movements.